Progesterone Lab Results: What Your Number Actually Changes About Your Treatment

What Progesterone Is and Why Clinicians Order It

Progesterone is a steroid hormone made primarily in the ovary after ovulation, in the placenta during pregnancy, and in small amounts by the adrenal glands. Your number tells a clinician whether you ovulated, whether a pregnancy is progressing, how well your corpus luteum is functioning, and whether hormone replacement doses need adjusting.

The test is a serum immunoassay. Results are reported in ng/mL in the United States; to convert to nmol/L (used in many international guidelines), multiply by 3.18.

What the Number Cannot Tell You Alone

A progesterone result is almost never interpreted in isolation. Clinicians cross-reference it with:

• Day of your cycle (or confirmed day of ovulation via LH surge or ultrasound)
• Estradiol level (the two hormones are interpreted as a pair in HRT monitoring)
• hCG (in early pregnancy, to assess whether progesterone is appropriate for gestational age)
• Symptoms (luteal spotting, short cycles, hot flashes, miscarriage history)

Without that context, a number of 8 ng/mL could mean a normal mid-luteal phase, a failing early pregnancy, or an inadequately managed HRT regimen. Same digit, three different clinical actions.

Normal Progesterone Ranges at Every Life Stage

Reference ranges shift so dramatically across a woman's life that a single table is not sufficient. Below are the ranges that matter clinically, with the caveats that govern each one.

Reproductive Years (Not Trying to Conceive)

The Endocrine Society's clinical practice guidelines describe progesterone as the gold-standard marker of ovulation when drawn in the mid-luteal phase, typically cycle days 19-22 in a 28-day cycle or 7 days after a confirmed LH surge.

• Follicular phase (days 1-13): <1 ng/mL. Progesterone is low and should be.
• Ovulatory surge: 1-3 ng/mL transiently.
• Mid-luteal phase (days 19-22): 5-20 ng/mL indicates ovulation occurred. Values above 3 ng/mL confirm ovulation at a minimum, but most reproductive endocrinologists want to see >5 ng/mL to feel confident in corpus luteum adequacy.
• Late luteal / premenstrual: Drops sharply toward 1 ng/mL as the corpus luteum involutes.

Cycles longer or shorter than 28 days mean the "day 21 draw" rule does not apply. A woman with a 35-day cycle should draw on approximately day 28.

Trying to Conceive and Anovulation

For women tracking fertility, the mid-luteal progesterone serves two purposes: confirming ovulation happened and assessing luteal phase quality. A mid-luteal value below 5 ng/mL in a woman who believed she ovulated suggests either she did not, or her corpus luteum output is insufficient.

A 2017 analysis in Fertility and Sterility found that a single mid-luteal progesterone below 9.4 ng/mL predicted a lower live-birth rate in IVF cycles, even after adjusting for age and embryo quality.

Women with PCOS often have anovulatory cycles, meaning progesterone stays in the follicular range (<1 ng/mL) throughout the month. That flat line across the cycle is itself diagnostic data. If you have PCOS and your mid-luteal draw returns below 2 ng/mL, your clinician will know ovulation did not occur that cycle regardless of whether you had a bleed.

Early Pregnancy

During early pregnancy, progesterone is made by the corpus luteum until the placenta takes over at 8-10 weeks (the luteo-placental shift). Reference values change week by week:

| Gestational Week | Typical Serum Progesterone | |---|---| | 4-6 weeks | 10-29 ng/mL | | 7-10 weeks | 17-146 ng/mL | | 11-15 weeks | 17-147 ng/mL | | Second trimester | 55-200 ng/mL | | Third trimester | 110-290 ng/mL |

A value below 5 ng/mL in early pregnancy is associated with a non-viable pregnancy in approximately 99% of cases, while a value above 20 ng/mL is strongly associated with a normally progressing intrauterine pregnancy.

Values between 5 and 20 ng/mL in the first trimester fall into a gray zone. Clinicians manage this zone with serial hCG draws every 48 hours, repeat progesterone, and ultrasound, not by treating the number alone.

Perimenopause

This is where interpretation becomes most nuanced, and where the evidence is thinnest. During perimenopause, cycles become irregular and anovulatory cycles increase. A woman can have a bleed that looks like a period with no ovulation behind it, meaning progesterone never rises that month.

According to The Menopause Society (formerly NAMS), progesterone and estradiol levels fluctuate widely in perimenopause and single measurements have limited diagnostic value. FSH is more commonly used to stage menopause transition, though it too is unreliable in early perimenopause.

If a perimenopausal woman is taking cyclic progesterone as part of hormone therapy, a trough level (drawn just before the next dose) of <0.5 ng/mL generally confirms she has metabolized the prior cycle's dose. Her symptom pattern, not a mid-cycle peak level, guides dose adequacy.

Postmenopause (No Hormone Therapy)

After menstrual cycles have stopped for 12 months, serum progesterone should be below 0.5 ng/mL and is often undetectable. Elevated progesterone in a postmenopausal woman who is not on hormone therapy warrants evaluation for adrenal pathology or, rarely, an ovarian tumor.

How a Low Progesterone Result Changes Your Treatment

Low progesterone means something different depending on why it is low, not just that it is low. Below are the four most common clinical scenarios.

Scenario 1: Low Progesterone Plus Irregular Cycles (Anovulation / PCOS)

If mid-luteal progesterone is below 3 ng/mL and you are not ovulating, the clinical target is to restore ovulation, not simply to supplement progesterone. Adding exogenous progesterone without inducing ovulation does not produce a normal luteal environment.

First-line options your clinician may discuss:

• Letrozole (preferred over clomiphene in PCOS per ACOG Practice Bulletin 194) to induce ovulation
• Metformin if insulin resistance is present, to restore spontaneous ovulation
• Weight-related interventions where applicable (a 5-10% weight reduction can restore ovulatory cycles in women with PCOS and elevated BMI, per the ESHRE/ASRM 2023 PCOS guideline)

Scenario 2: Low Mid-Luteal Progesterone in a Woman Who Did Ovulate (Luteal Phase Defect)

Luteal phase defect (LPD) is defined as inadequate progesterone production from a corpus luteum that formed after ovulation. The ASRM Practice Committee notes that diagnosing LPD remains contested, and no single progesterone threshold has been universally accepted.

Practically, if a woman has a confirmed LH surge, a mid-luteal draw below 5 ng/mL on a timed cycle, and symptoms such as spotting before her period, short luteal phases (less than 11 days), or a history of recurrent early miscarriage, most reproductive endocrinologists will offer a trial of vaginal or oral progesterone supplementation in the luteal phase.

Scenario 3: Low Progesterone in Early Pregnancy

A Cochrane review published in 2021 found that vaginal progesterone reduces the rate of miscarriage in women with a history of recurrent pregnancy loss and a viable pregnancy on ultrasound. The absolute risk reduction was approximately 8 percentage points.

The PRISM trial, published in NEJM 2019, found that vaginal progesterone 400 mg twice daily significantly increased the live-birth rate in women presenting with first-trimester bleeding who had a viable intrauterine pregnancy on ultrasound, from 72% to 76% (absolute difference 4 percentage points, NNT approximately 25).

If your progesterone is low in early pregnancy and you have a confirmed viable intrauterine pregnancy with cardiac activity, your clinician may prescribe vaginal progesterone supplementation. The dose used in PRISM was 400 mg vaginally twice daily starting before 12 weeks.

Scenario 4: Low Progesterone on Hormone Therapy

If you are taking a progestogen as part of menopausal hormone therapy and your level is unexpectedly low, the most likely explanation is formulation or timing. Oral micronized progesterone (Prometrium) has high first-pass hepatic metabolism, meaning serum levels after an oral 100 mg or 200 mg dose are much lower than after the same dose vaginally. Peak oral progesterone levels reach approximately 2-3 ng/mL at 1-2 hours and then fall quickly.

This matters because endometrial protection from oral micronized progesterone depends on total exposure, not peak serum level. Checking a random trough progesterone in a woman on cyclic oral progesterone will produce a number that looks low but may still be adequate for endometrial protection if she is taking it correctly and consistently.

How a High Progesterone Result Changes Your Treatment

High progesterone in a non-pregnant woman almost always means one of three things: the draw was timed to the luteal phase (expected and normal), there is an exogenous source (HRT, IVF supplementation), or, rarely, there is an adrenal or ovarian source requiring evaluation.

High Progesterone During HRT or IVF

If you are on progesterone supplementation for IVF or frozen embryo transfer (FET), your clinic will have protocol-specific target ranges. Most FET protocols aim for a serum progesterone above 10 ng/mL on the day of transfer when using injectable progesterone-in-oil. A 2021 study in Fertility and Sterility found that serum progesterone below 10.46 ng/mL on transfer day was associated with a significantly lower ongoing pregnancy rate.

High Progesterone in a Non-Pregnant, Non-Supplemented Woman

A mid-cycle (follicular phase) progesterone above 1.5 ng/mL, or any luteal-phase value above 40 ng/mL without exogenous supplementation, warrants further investigation. The differential includes:

• Congenital adrenal hyperplasia (CAH), particularly 21-hydroxylase deficiency, which can cause elevated 17-hydroxyprogesterone (a different but related test)
• Adrenal tumor or hyperplasia
• Ovarian steroidogenic tumor
• Lab error (the most common reason for unexpected values)

The Endocrine Society clinical practice guideline on adrenal incidentaloma recommends endocrinology referral and 24-hour urine steroid profiling when adrenal pathology is suspected.

Progesterone, Pregnancy, and Lactation: What You Need to Know

This section covers the safety of progesterone supplementation rather than the endogenous hormone.

Pregnancy Safety

Supplemental progesterone in pregnancy is classified as FDA Pregnancy Category B for vaginal formulations used to support early pregnancy and prevent preterm birth in high-risk women. No controlled trials have demonstrated teratogenicity at clinical doses. The ACOG Practice Bulletin on preterm labor prevention (No. 234) recommends vaginal progesterone 200 mg nightly for women with a singleton pregnancy and a short cervix (cervical length <20 mm before 24 weeks).

Oral micronized progesterone is not typically used to prevent preterm birth because it is metabolized to allopregnanolone and other neuroactive steroids, which may cause sedation. Vaginal administration bypasses most of that first-pass conversion.

Synthetic progestogens (medroxyprogesterone acetate, norethindrone) should not be used in early pregnancy. They carry no benefit and older androgenic synthetic progestins carry theoretical virilization risk.

Lactation

Endogenous progesterone drops sharply after delivery of the placenta. That drop is the hormonal trigger for milk coming in (lactogenesis II). Supplemental micronized progesterone is not routinely given postpartum to breastfeeding women. If progesterone is needed postpartum (for example, to manage heavy bleeding or as part of HRT), the lowest effective dose and vaginal route are generally preferred to minimize transfer into breast milk. LactMed, the NLM database on drugs and lactation, notes that endogenous progesterone is present in breast milk at physiological concentrations and that clinical doses of supplemental progesterone are unlikely to harm a nursing infant, though data are limited.

Contraception Consideration

Women using progesterone supplementation for luteal support during fertility treatment are, by definition, trying to conceive. No contraception concern applies in that context.

For women prescribed continuous high-dose progesterone for conditions such as endometriosis or as part of the progestin-only mini-pill, it is the progestogen itself that provides contraceptive effect. Stopping it abruptly without a contraceptive plan creates pregnancy risk.

Who This Is Right For (and Who Needs a Different Approach)

A serum progesterone draw is appropriate for:

• Women tracking ovulation who want objective confirmation beyond LH strips
• Women with suspected luteal phase defect, irregular cycles, or anovulation
• Women with a history of recurrent pregnancy loss (first-trimester)
• Women on HRT who have new breakthrough bleeding or symptoms suggesting hormone imbalance
• Women undergoing IVF or FET (protocol-mandated monitoring)
• Postmenopausal women with unexplained symptoms or unexpected lab findings

A progesterone draw is less useful for:

• Diagnosing menopause (FSH plus symptom history is the standard approach)
• Routine annual labs in a woman with regular cycles and no symptoms
• Assessing overall hormonal health as a standalone number (a hormone panel in context is more informative)

Women with PCOS deserve a specific note. Because ovulation is irregular or absent, a randomly timed progesterone gives almost no information. If your cycle day is unknown or cycles are unpredictable, your clinician should time the draw to a confirmed LH surge or skip the test in favor of a structured anovulation workup.

What Your Clinician Looks at Alongside Progesterone

Progesterone does not travel alone on a lab report. Here is the interpretive pair for each clinical context:

| Clinical Context | Progesterone + | Key Question | |---|---|---| | Ovulation confirmation | LH surge timing | Did I ovulate this cycle? | | Luteal phase defect | Cycle day, symptom diary | Is corpus luteum output adequate? | | Early pregnancy loss | Serial hCG, ultrasound | Is this pregnancy viable? | | PCOS / anovulation | Testosterone, LH:FSH ratio, AMH | What is driving the cycle problem? | | Perimenopause | Estradiol, FSH, symptom severity | Where am I in the transition? | | HRT monitoring | Estradiol, symptom log, endometrial thickness | Is the regimen working and safe? |

The Evidence Gap: A Candid Note

Reference ranges for serum progesterone were largely established in studies enrolling predominantly White women of reproductive age with regular cycles. Data on progesterone norms in:

• Women of Black or Hispanic ethnicity are limited. A 2018 analysis in AJOG found that endocrine reference ranges may not translate uniformly across ethnic groups.
• Women in the perimenopause transition are particularly poorly served. Single-point progesterone values during perimenopause have wide within-person variability that makes cross-sectional reference ranges nearly meaningless.
• Women with thyroid disease may have altered progesterone metabolism. Hypothyroidism can impair corpus luteum function and lower luteal progesterone even in ovulatory cycles, per a 2017 review in the Journal of Clinical Endocrinology and Metabolism.

When your result is borderline, the honest answer is often "we need more context," not a binary normal/abnormal call. Any clinician who makes a major treatment decision on one untimed progesterone number is working beyond what the evidence supports.

Two Direct Clinical Voices on Progesterone Interpretation

The ASRM Practice Committee position on luteal phase deficiency states: "A single serum progesterone measurement during the mid-luteal phase is the most commonly used test for confirmation of ovulation, but it is a poor predictor of reproductive outcome."

The Menopause Society's 2023 hormone therapy position statement, available at menopause.org, notes that "serum progesterone monitoring is not required for most women on standard-dose menopausal hormone therapy," because the clinical goal of progesterone in HRT is endometrial protection, and that endpoint is monitored by symptom pattern and endometrial biopsy or ultrasound rather than serum level.

Practical Steps After Getting Your Result

If your result is below 3 ng/mL and you expected to be in the luteal phase: confirm the draw was timed correctly before assuming a problem. A follicular-phase or early-luteal draw will always look low.

If timing was correct and you are trying to conceive: request a repeat draw 2-3 days later, along with LH and estradiol, and discuss whether ovulation induction or luteal support is appropriate.

If you are in early pregnancy and your value is in the gray zone (5-15 ng/mL): do not panic based on the number alone. Serial hCG and an early ultrasound at 6-7 weeks provide far more actionable information than a single progesterone.

If you are on HRT and your clinician ordered a progesterone check: ask what specific clinical question the test is meant to answer. If the answer is "endometrial protection," know that serum level is not the right tool. Endometrial thickness on transvaginal ultrasound, or biopsy, answers that question directly.

If your result is above 20 ng/mL and you are not in the luteal phase and not supplementing: ask your clinician to check the timing, repeat the draw, and consider whether adrenal or ovarian evaluation is warranted.

Your next progesterone draw should be timed to 7 days after your confirmed LH surge, not to a calendar date, for the most clinically meaningful result.